Abstract 388P
Background
More and more evidences suggest that circulating tumor cells (CTC) may be a good biomarker, not only as a prognostic indicator for tumors, but also for monitoring therapeutic effect and recurrence. However, the detection of CTC usually requires the final artificial judgment. This requires experienced pathologists and increases their workload. The application of machine learning in medical image recognition can effectively improve the level of automation and reduce the workload. So we hope to use machine learning to identify CTCs.
Methods
First, the python's openCV software package is used to segment the images of CTCs by image denoising, image filtering, edge detection, image expansion and contraction techniques. Secondly, the segmented cell images as a training set are trained using the CNN deep learning network. The CNN deep learning network includes input layer, intermediate hidden layer, and output layer. The middle hidden layer contains three layers, namely layer1, layer2 and lager3. Each intermediate hidden layer further includes convolution layer, excitation layer, and pooling layer. After the input layer, the cell images first enter the first intermediate hidden layer. The convolution layer of the first intermediate hidden layer is composed of 32 5x5 convolution kernels, which are then output to the pooling layer for dimension reduction through the ReLU excitation layer. After dimension reduction, the data is output from the first hidden layer to complete an entire feature extraction process. Then, through the second and third intermediate hidden layers in sequence, all feature extraction is completed. Finally, it enters the output layer and output the result, ie, CTCs or non-CTCs.
Results
We took 2920 cells from 732 patients for training and testing. Among them, 2000 cells were used as training set and 920 cells were used as testing set. The sensitivity and specificity of recognition reached 86.1% and 84.5%, respectively.
Conclusions
To identify CTC by machine learning can reach high sensitivity and specificity. We are further revising our methods of deep learning to achieve greater recognition effect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
528P - High-biologically effective dose radiotherapy may improve local control of small cell lung cancer patients with brain metastases: A propensity-matching analysis
Presenter: Qingyang Zhuang
Session: Poster display session
Resources:
Abstract
530P - Prognostic value of C-reactive protein, albumin and C-reactive protein to albumin ratio in small cell lung cancer: A meta-analysis
Presenter: Carla Emille Barbon
Session: Poster display session
Resources:
Abstract
531TiP - CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC
Presenter: Byoung Chul Cho
Session: Poster display session
Resources:
Abstract
532TiP - CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC
Presenter: Daniel Shao Weng Tan
Session: Poster display session
Resources:
Abstract
533TiP - CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx)
Presenter: Darren Lim
Session: Poster display session
Resources:
Abstract
534TiP - A randomized phase III study of carboplatin plus nab-paclitaxel with or without nintedanib for NSCLC with IPF (J-SONIC)
Presenter: Kohei Otsubo
Session: Poster display session
Resources:
Abstract
535TiP - Phase II study of atezolizumab for pretreated advanced / recurrent non-small cell lung cancer with idiopathic interstitial pneumonia (TORG1936 / AMBITIOUS study)
Presenter: Satoshi Ikeda
Session: Poster display session
Resources:
Abstract
536TiP - INSIGHT 2: Tepotinib plus osimertinib in patients with EGFR-mutant NSCLC having acquired resistance to EGFR TKIs due to MET-amplification: A phase II trial in progress study
Presenter: James C-H Yang
Session: Poster display session
Resources:
Abstract
YO8 - Carcinosarcoma of the Breast in a Filipino Female: A Case Report
Presenter: Ma. Angelle Lalaine Dantes
Session: Poster display session
Resources:
Abstract
YO9 - Small Malignant Phyllodes Tumor of the Breast with Metastases to the Lung and Bone
Presenter: Gusti Harti
Session: Poster display session
Resources:
Abstract